Last reviewed · How we verify

Methylphenidate (MPD)

University of Cincinnati · FDA-approved active Small molecule

Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability in the brain.

Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability in the brain. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.

At a glance

Generic nameMethylphenidate (MPD)
Also known asRitalin
SponsorUniversity of Cincinnati
Drug classSympathomimetic amine; CNS stimulant
TargetDopamine transporter (DAT); Norepinephrine transporter (NET)
ModalitySmall molecule
Therapeutic areaNeurology; Psychiatry
PhaseFDA-approved

Mechanism of action

Methylphenidate is a sympathomimetic amine that inhibits the reuptake transporters (DAT and NET) for dopamine and norepinephrine, leading to increased concentrations of these neurotransmitters in the synaptic cleft. This enhanced dopaminergic and noradrenergic signaling improves attention, focus, and impulse control in patients with attention deficit hyperactivity disorder and narcolepsy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: